Overview

Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy

Status:
Completed

Trial end date:
2004-12-01

Target enrollment:

Participant gender:

Summary

To collect under daily practice conditions, clinical data on the changes of sexual function when a new formulation of alfuzosin(Xatral XL® )is administered once daily in patients with lower urinary tract symptoms(LUTS) suggestive of prostatic hypertrophy

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Treatments:

Alfuzosin